Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved). This article does not constitute any investment advice.
Recently, Baixi Ousi (Beijing) Biological Technology Co., Ltd. ("Baixi Ousi") announced the completion of a multi-million RMB B+ round of financing led by Green Pine Capital, with participation from Xiamen Hi-tech Angel Investment Co., Ltd. and Cheng Du Sheng Nuo Biotec Co., Ltd. Existing shareholder Beijing Science Sun Pharmaceutical Co., Ltd. continued to increase its investment. The funds raised in this round will be used to advance the Phase II clinical trial of BXOS110, a Class 1 innovative drug for treating ischemic stroke, as well as the IND applications for two other Class 1 innovative drugs, BXOS116 and BXOS401, aimed at neural repair and regeneration during the stroke recovery period.With the increasing degree of aging in China and changes in people's lifestyles, China has become one of the countries with the highest incidence of stroke in the world. Stroke has now become the leading cause of death among Chinese citizens and is the disease with the highest single-cause disability rate. Stroke is divided into two main categories: ischemic stroke and hemorrhagic stroke, with ischemic stroke being the most common type, accounting for 70%-80% of all strokes. Ischemic stroke is caused by the blockage of cerebral blood vessels, leading to an interruption in the supply of blood, oxygen, and nutrients to brain tissue, resulting in irreversible damage to the brain. It also causes a series of cognitive, motor, and emotional impairments in patients, severely affecting their quality of life and placing a significant burden on society and families.In China, a new stroke patient is identified every 12 seconds. According to the Global Burden of Disease (GBD) data, in 2019, there were 3.94 million new stroke cases in China, with the total number of stroke patients reaching 28.76 million and stroke-related deaths amounting to 2.19 million. Under the new treatment model of "vascular recanalization + neuroprotection" for stroke, the sales revenue of neuroprotective agents reached nearly 18 billion yuan in 2022, and the market size is expected to reach nearly 33 billion yuan by 2030.Baixi Ousi (Beijing) Biological Technology Co., Ltd. is a national high-tech enterprise specializing in the field of neurological diseases, and has received multiple honors and qualifications such as a national technology-based small and medium-sized enterprise and a Beijing specialized, refined, distinctive, and innovative small and medium-sized enterprise. The company focuses on the prevention and treatment of neurological damage throughout the entire stroke disease cycle, neuroprotection for ischemic and hemorrhagic strokes, brain edema, and nerve repair, all of which address significant unmet clinical needs.The company has a small molecule and peptide drug discovery platform, an in vitro molecular and cellular level drug screening platform, and an in vivo animal level efficacy evaluation platform, with a complete system for drug design, screening, evaluation, CMC, and clinical research. The core R&D team of Baixi Ousi (Beijing) Biological Technology Co., Ltd. consists of multiple members from the former Academy of Military Medical Sciences, the Chinese Academy of Sciences, and overseas Ph.D. teams, with profound expertise in drug design and screening of peptides and small molecules, as well as pharmacology and toxicology evaluation.Tian Qiuping, Chairman of Baixi Ousi (Beijing) Biological Technology Co., Ltd., stated: "We are very grateful for the participation of new shareholders such as Green Pine Capital, Xiamen Hi-tech Angel Investment Co., Ltd., Science Sun, and Cheng Du Sheng Nuo Biotec Co., Ltd., as well as the continued support from existing shareholders at this critical juncture. We will continue to advance the Phase 2 clinical trial of BXOS110, which is a milestone. BXOS110 is the company's first Class 1 innovative drug to enter clinical trials, intended for neuroprotection in the ultra-acute phase of acute stroke. At the same time, we will also actively promote the clinical translation of BXOS116 and BXOS401, used for neural repair and regeneration during the stroke recovery phase, achieving a pipeline layout covering the entire disease cycle of stroke, and developing truly effective innovative drugs that address unmet clinical needs in the field of stroke. Green Pine Capital is a well-known investment institution with extensive experience in biopharmaceutical investments, and their participation provides both financial and professional support for the rapid and healthy development of our company."Zhang Chong, Managing Director of Green Pine Capital, stated: "Baixi Ousi chose such a challenging field to quietly cultivate when the company was initially established, and has accumulated over a decade of experience in innovative drug development for stroke. To date, the company has built an efficient R&D team in areas such as molecular design, drug screening, animal experiments, CMC, clinical trials, and patent protection. We look forward to Baixi Ousi achieving success soon in the field of innovative drugs for stroke treatment, benefiting all humanity."Science Sun Chairman Ma Biao stated: "We have always paid special attention to the NA-1 variety. It is the first drug proven to potentially have a neuroprotective effect when applied early after acute ischemic stroke, filling the gap for drugs within the time window. We have high hopes for the Baixi Ousi team and their product pipeline. As the saying goes, 'Plum blossoms' fragrance comes from enduring bitter cold.' Once the interim results of the Phase II trial are unblinded, it will certainly become a blockbuster product. Our company has long been committed to the field of peptide innovative drugs, which aligns well with our group's strategy. We are willing to continue investing and accompany Baixi Ousi in achieving further success in the field of innovative stroke drugs."Wen Yongjun, Chairman of Cheng Du Sheng Nuo Biotec Co.,ltd., stated: "Innovation requires not only breakthrough ideas but also long-term, dedicated efforts. The team at Baixi Ousi (Beijing) Biological Technology Co., Ltd. has adhered to this principle, building and refining an efficient R&D team. They have achieved remarkable success in the development of innovative drugs for stroke and nervous system-related diseases. We look forward to the early market launch of Baixi Ousi’s innovative stroke treatment drug, which will benefit patients."Xiamen Hi-tech Angel Investment Co., Ltd. stated: "Baixi Ousi focuses on innovative drugs for a variety of neurological-related diseases, including stroke and brain edema, screening out multiple candidate drug molecules that have advanced to clinical trials or are about to submit IND applications, showcasing the professionalism and efficiency of Baixi Ousi's R&D team. In the future, we look forward to working hand in hand with Baixi Ousi to continue exploring treatments for stroke and other neurological-related diseases, benefiting patients as soon as possible."Source: Securities Times Network
